Merck & Co saw worldwide sales fall by 8% in the first quarter of 2015 but major products met expectations – including diabetes therapy Januvia (sitagliptin), which received further positive news on 27 April when Merck reported the drug didn't increase the risk of heart problems in patients.
Full results of the cardiovascular outcomes (CVOT) trial for the di-peptidyl peptidase-IV (DPP-4) Januvia will be reported at the American Diabetes Association's annual meeting on 8 June, but Merck said...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
